ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：217
|
作者：
Cang, Shundong [1 ]
Iragavarapu, Chaitanya [2 ,3 ]
Savooji, John [2 ,3 ]
Song, Yongping [4 ,5 ]
Liu, Delong [4 ,5 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Valhalla, NY 10595 USA
[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;
D O I：
10.1186/s13045-015-0224-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
    Deng, Jing
    Letai, Anthony
    BREAST CANCER RESEARCH, 2013, 15 (05)
  • [22] MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells
    Wang, Qing
    Wan, Jiangbo
    Zhang, Wenhao
    Hao, Siguo
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2170 - 2180
  • [23] Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis
    Tian, Bao-Ping
    Li, Fangyuan
    Li, Ruiqing
    Hu, Xi
    Lai, Tian-Wen
    Lu, Jingxiong
    Zhao, Yun
    Du, Yang
    Liang, Zeyu
    Zhu, Chen
    Shao, Wei
    Li, Wen
    Chen, Zhi-Hua
    Sun, Xiaolian
    Chen, Xiaoyuan
    Ying, Songmin
    Ling, Daishun
    Shen, Huahao
    BIOMATERIALS, 2019, 192 : 429 - 439
  • [24] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Leverson, Joel
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [25] ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+-signalling dysregulation or toxicity in pancreatic acinar cells
    Jakubowska, Monika A.
    Kerkhofs, Martijn
    Martines, Claudio
    Efremov, Dimitar G.
    Gerasimenko, Julia V.
    Gerasimenko, Oleg V.
    Petersen, Ole H.
    Bultynck, Geert
    Vervliet, Tim
    Ferdek, Pawel E.
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (22) : 4402 - 4415
  • [26] Dual Targeting of Ph plus ALL with Dasatinib and ABT-199 (Venetoclax)
    Leonard, Jessica
    Rowley, Joelle
    Hayes-Lattin, Brandon
    Tyner, Jeffrey W.
    Loriaux, Marc
    Druker, Brian J.
    Chang, Bill H.
    BLOOD, 2015, 126 (23)
  • [27] Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
    Cai, Tianyu
    Kuruvilla, Vinitha
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Zhang, Qi
    Han, Lina
    Cavazos, Antonio
    Shen, Yu
    Konopleva, Marina
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer
    Lindeman, G. J.
    Vaillant, F.
    Merino, D.
    Lee, L.
    Breslin, K.
    Pal, B.
    Ritchie, M. E.
    Smyth, G. K.
    Christie, M.
    Phillipson, L. J.
    Burns, C. J.
    Mann, G. B.
    Visvader, J. E.
    CANCER RESEARCH, 2013, 73
  • [29] BCL-2选择性抑制剂——ABT-199的合成工艺改进
    许云雷
    葛敏
    合成化学, 2015, 23 (11) : 1063 - 1067
  • [30] Arsenic Trioxide Synergistically Enhances the Antileukemia Activity of Bcl-2 Inhibitor ABT-199 in Acute Myeloid Leukemia
    Liu, Sha
    Chen, Lin
    Wang, Xiaojiao
    Mi, Ruihua
    Yin, Qingsong
    Fan, Ruihua
    Wei, Xudong
    BLOOD, 2019, 134
12345